ArticleInternational journal of clinical and experimental pathology2015
The role of high mobility group box 1 (HMGB-1) in the diabetic retinopathy inflammation and apoptosis.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Sorafenib nanoparticles coated with Eudragit RL for ocular drug delivery: a potential treatment for diabetic retinopathy.International journal of pharmaceutics: X · 2026Article
- Current Perspectives of TLR2 Signalling in the Retina.Advances in experimental medicine and biology · 2025Review
- Restoring glucose balance: Conditional HMGB1 knockdown mitigates hyperglycemia in a Streptozotocin induced mouse model.Heliyon · 2024Article
- High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: AnCartilage · 2021Article
- Protective role and molecular mechanism of action of Nesfatin-1 against high glucose-induced inflammation, oxidative stress and apoptosis in retinal epithelial cells.Experimental and therapeutic medicine · 2021Article
- Quercetin protects against diabetic retinopathy in rats by inducing heme oxygenase-1 expression.Neural regeneration research · 2021Article
- The Complex Relationship between Diabetic Retinopathy and High-Mobility Group Box: A Review of Molecular Pathways and Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2020Review
- High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives.International journal of molecular sciences · 2019Review
- Alcohol-dependent pulmonary inflammation: A role for HMGB-1.Alcohol (Fayetteville, N.Y.) · 2019Article
- Novel understanding of high mobility group box-1 in the immunopathogenesis of incisional hernias.Expert review of clinical immunology · 2019Review
- Can Epigenetics of Endothelial Dysfunction Represent the Key to Precision Medicine in Type 2 Diabetes Mellitus?International journal of molecular sciences · 2019Review
- Serum levels of the high-mobility group box 1 protein (HMGB1) in children with type 1 diabetes mellitus: case-control study.Central-European journal of immunology · 2019Article
- Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging.Aging and disease · 2018Review
- HMGB1 contributes to the irradiation-induced endothelial barrier injury through receptor for advanced glycation endproducts (RAGE).Journal of cellular physiology · 2018Article
- High glucose concentration induces retinal endothelial cell apoptosis by activating p53 signaling pathway.International journal of clinical and experimental pathology · 2018Article
- Expression of High-Mobility Group Box 1 Protein (HMGB1) and Toll-Like Receptor 9 (TLR9) in Retinas of Diabetic Rats.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- HMGB1 siRNA can reduce damage to retinal cells induced by high glucose in vitro and in vivo.Drug design, development and therapy · 2017Article
- High Mobility Group Box-1: A Missing Link between Diabetes and Its Complications.Mediators of inflammation · 2016Review
- The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes.Journal of diabetes research · 2016Review
- The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target.Diabetes & vascular disease researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Retinopathy (DR) is one of the most common complications of the late phase diabetes, and also a common cause of blindness. High mobility group box 1 (HMGB-1) is considered to be an inflammatory mediator in the late phase that promotes inflammation and neovascularization in diabetes. Therefore, this paper discussed the role of HMGB-1 in diabetic retinopathy inflammation and neovascularization. 96 adult SD rats were randomly divided into control and diabetes group. The diabetic rat model was established by intraperitoneal injection of streptomycin (0.1 mol/L). Western blot was applied to determine HMGB-1 and its receptor RAGE and TLR2 protein expression in the serum. TUNEL was used to detect retinal apoptosis. Immunofluorescence was performed to test HMGB1 protein expression in retina. HBGM-1 and RAGE expression in diabetic rat retina was significantly higher than the control (P < 0.05), while TLR2 expression was lower (P < 0.05). TUNEL detection showed that diabetic rat retinal cells presented obviously higher apoptosis rate (P < 0.05). Immunofluorescence test revealed that HMGB1 largely expressed in the diabetic rat retinal cells (P < 0.05). HMGB1 may involve in the pathogenesis of diabetic retinopathy by binding with RAGE receptor to accelerate rat retinal cells apoptosis.
Indexed as
Identifiers
26261566PMC4525900W1130520616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.